Predictive Oncology (NASDAQ: POAI), together with its subsidiary, TumorGenesis, Inc., today announced that it has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor of its innovative culture media for growing ovarian tumor cells. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological signatures … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches Innovative Culture Media for Growing Ovarian Tumor Cells in the Lab”
Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, possesses a unique advantage over its competition in the form of samples and access to historical data on clinical outcomes. This data could enable POAI to produce value to pharmaceutical companies significantly faster than its competitors. An article discussing the company reads, “Specifically, … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Unique Competitive Advantage”
Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, today announced that it has signed a letter of intent (“LOI”) to acquire Quantitative Medicine (“QM”), a biomedical analytics and computational biology company. By combining QM’s CoRE predictive modeling platform with POAI’s tumor profiling proficiency and data, company management believes the acquisition will … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Inks LOI to Acquire Quantitative Medicine”
New board member, audit committee chair brings 35 years of accounting experience, mainly in management Prior worked as CFO, controller in several genomics, health companies POAI to leverage Prior’s new insights, guidance in the financial space Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, announced that Pam Prior, CPA, has been … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member, Audit Committee Chair”
Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, recently issued an update regarding its groundbreaking CancerQuest 2020 initiative driven by its Helomics subsidiary (http://nnw.fm/y6fnc). Per the update, the company intends to have its first predictive model of ovarian … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Aims to Commercialize AI-Driven Predictive Model of Ovarian Cancer in Q1 2020”
American Cancer Society annual report shows largest single-year drop in cancer deaths ever reported Doctors attribute precision medicine with playing significant role in decline POAI leading player in precision medicine, initiated groundbreaking Cancer Quest 2020 project A new American Cancer Society report bodes well for Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI), Leader in Precision Medicine, Committed to Playing Key Role in Decreasing Cancer Deaths”
The global precision medicine market is estimated to reach $84.6 billion by 2024 Predictive Oncology is bringing cutting-edge technology to cancer research to develop highly customizable assessment methods that improve patient outcomes POAI leverages unique competitive advantage that stems from readily available access to historical data on tumor profiles and their drug responses Precision medicine, … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) Disruptive Platform Overcoming Obstacles in Precision Medicine Industry”
POAI plans to have first predictive model of ovarian cancer ready for initial commercialization in Q1 2020 First batch of 400 ovarian cancer subjects in initiative has been sequenced Groundbreaking AI-driven model of ovarian cancer will be capable of predicting tumor drug response, patient outcome Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Working to Create World’s First Comprehensive, Actionable Multi-Omic Data Set for Ovarian Cancer”
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the unanimous appointment of Pam Prior, CPA, to its Board of Directors. According to the update, Prior is the founder and CEO of Priorities Group, … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Appointment of Pam Prior to its Board of Directors”
Predictive Oncology (NASDAQ: POAI), through its subsidiary Helomics, is sequencing ovarian cancers as part of a CancerQuest 2020 project, building the largest ovarian multi-omic database in the world. An article discussing the company reads, “As part of its CancerQuest 2020 project, Predictive Oncology, through Helomics, recently signed a collaborative agreement with UPMC-Magee to establish a … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building AI-driven Ovarian Cancer Model to Predict Tumor Drug Response, Patient Outcome”
